A Study of LNK01002 in Patients With Primary or Secondary Myelofibrosis,Polycythemia Vera or Acute Myeloid Leukemia

Phase 1

Withdrawn

• Conditions: Primary Myelofibrosis; Acute Myeloid Leukemia; Polycythemia Vera; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
• Interventions: Drug: LNK01002

• Registration Number: NCT04896112
• Lead Sponsor: Lynk Pharmaceuticals Co., Ltd

Brief Summary

This multicenter, open-label, phase 1 study designed to evaluate safety and tolerability of multi-kinase inhibitor LNK01002 in patients with primary myelofibrosis (PMF), or MF due to polycythemia vera (PV-MF), or essential thrombocythemia (ET-MF), polycythemia vera (PV), or with acute myeloid leukemia (AML).

Detailed Description

This is a Phase I, open-label, dose-finding study of the triple kinase inhibitor LNK01002 in patients with Malignant Myeloid Hematologic Neoplasms. The study consists of two periods: the dose escalation, main period and a dose expansion period. In the dose escalation period, successive cohorts of patients with Malignant Myeloid Hematologic Neoplasms will be enrolled to establish the maximum tolerated dose. In the dose expansion period (dose-confirmation phase), three cohorts of patients will be enrolled: AML patients with confirmed FLT3-ITD mutations, AML patients without FLT3-ITD mutations, and patients with primary MF ,PV or PV/ET-MF.

The safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary clinical activity of LNK01002 in patients with Malignant Myeloid Hematologic Neoplasms will be evaluated.

Study Timeline

• Study Start: 2021-04-08
• Study First Submitted: 2021-05-08
• Study First Submitted QC: 2021-05-17
• Study First Posted: 2021-05-21
• Primary Completion: 2022-10-20
• Study Completion: 2022-10-20
• Status Verified: 2023-06
• Last Update Submitted: 2023-06-15
• Last Update Posted: 2023-06-18

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

1. Age: 18 years old or older, male or female.

2. Patients must have histologically or cytologically confirmed tumors of the following types.

   • Dose Escalation Phase: Patients with PMF,PV/ET-MF,PV

     1. Intermediate or high-risk primary myelofibrosis, intermediate or high-risk post-polycythemia vera myelofibrosis , or post-essential thrombocythemia myelofibrosis , or high-risk polycythemia vera who have no available therapy or relapsed after allogeneic hematopoietic cell transplantation.
     2. Symptomatic splenomegaly
     3. Not undergone splenectomy or splenic radiation therapy within 6 months prior to screening.

   • Dose expansion phase: Patients with PMF, PV/ET-MF,PV who relapsed or are intolerant to standard treatment, and relapsed/refractory AML

3. Platelet count ≥ 100 × 10e9/L within 14 days before study drug administration

4. Absolute neutrophil count (ANC) ≥ 1.5 × 10e9/L within 14 days before study drug administration

5. Women of childbearing potential negative pregnancy test at screening. Female patients of childbearing potential, or male patients and their partners should agree to effective contraception from signing ICF until 6 months after the last dose of study drug.

Exclusion Criteria

Patients who meet any of the following exclusion criteria will be excluded from the clinical study:

1. Allergic to any component of LNK01002.

2. Serum total bilirubin greater than 1.5 times the upper limit of the normal (ULN) reference range, except patients diagnosed as Gilbert's disease

3. ALT or AST higher than 3 times the ULN reference range without hepatic involvement by leukemia, which are excluded if higher than 5 times the ULN

4. Glomerular filtration rate or estimated creatinine clearance < 50 mL/min according to the Cockcroft-Gault formula;

5. Serum amylase or lipase levels higher than the ULN and considered clinically significant

6. International normalized ratio (INR) or partial activated prothrombin time (aPTT) above 1.5 times the ULN reference range

7. Known history of clinically significant liver disease, including viral or other hepatitis:

   a) Patients with hepatitis B or hepatitis C may be enrolled if they have a negative polymerase chain reaction (PCR)

8. Known human immunodeficiency virus (HIV) infection;

9. Clinically significant cardiovascular diseases, including acute myocardial infarction, unstable angina, coronary artery bypass surgery within 6 months before enrollment, congestive heart failure with New York Heart Association (NYHA) classification of III or above, left ventricular ejection fraction (LVEF) < 50%, or uncontrolled hypertension, cardiac arrhythmia;

10. Patients with history or presence of clinically relevant non-malignant CNS disease requiring treatment;

11. Patients who have received systemic antineoplastic therapy or radiotherapy within 2 weeks prior to start of study treatment;

12. Patients who have received hematopoietic stem cell transplantation (HSCT) within 60 days prior to the start of study treatment, or are receiving immunosuppressive therapy after HSCT at screening, or have graft-versus-host disease (GVHD) requiring ongoing treatment;

13. Received anti-tumor Chinese herbal medicine treatment within 1 week before the start of study treatment;

14. Received CYP3A strong inhibitors or strong inducers less than one week or 5 half-lives (whichever is longer) prior to the start of study treatment;

15. Uncontrolled, active infections requiring intravenous antibiotic treatment;

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SEQUENTIAL

Arm && Interventions

Group	Intervention	Description
Patients with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 60 mg	LNK01002	LNK01002 60 mg BID, followed by a 3-day observation period then 60 mg BID in 28-day treatment cycles
Patient with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 15 mg	LNK01002	Single dose of LNK01002 15 mg; followed by a 3-day observation period then 15mg BID in 28-day treatment cycles
Patients with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 100 mg	LNK01002	LNK01002 100 mg BID, followed by a 3-day observation period then 100 mg BID in 28-day treatment cycles
Patients with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 150 mg	LNK01002	LNK01002 150 mg BID, followed by a 3-day observation period then 150 mg BID in 28-day treatment cycles
Patients with Primary or Secondary Myelofibrosis,PV	LNK01002	LNK01002 at the RP2D dose in 28-day treatment cycles
Patients with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 30 mg	LNK01002	LNK01002 30 mg twice daily (BID), followed by a 3-day observation period then 30 mg BID in 28-day treatment cycles
Patients with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 200 mg	LNK01002	LNK01002 200 mg BID, followed by a 3-day observation period then 200 mg BID in 28-day treatment cycles
Patients with Malignant Myeloid Hematologic Neoplasms treated with LNK01002 260 mg	LNK01002	LNK01002 260 mg BID, followed by a 3-day observation period then 260 mg BID in 28-day treatment cycles
Patients with Acute Myeloid Leukemia With Mutant FLT3	LNK01002	LNK01002 at the RP2D dose in 28-day treatment cycles
Patients with Malignant Myeloid Hematologic Neoplasms Without Mutant FLT3	LNK01002	LNK01002 at the RP2D dose in 28-day treatment cycles

Primary Outcome Measures

Name	Time	Method
Assessing the safety and tolerability of LNK01002 in patients with Malignant Myeloid Hematologic Neoplasms	31 days	Assessed by monitoring the frequency, duration and severity of adverse events and serious adverse events.
Assessing the preliminary antitumor activity of LNK01002	24 Weeks	The preliminary antitumor activity will be analyzed in patients with different types of malignant myeloid hematologic neoplasms by response rate using bone marrow and hematologic analyses (MF/AML) or by the MF Symptom Assessment Scale and spleen volume by MRI (MF).
Assessing maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) of LNK01002 in patients with Malignant Myeloid Hematologic Neoplasms	31 days	Maximum tolerated dose (MTD) and/or recommended phase II dose (RP2D) will be assessed based on the safety profile by the SRC

Secondary Outcome Measures

Name	Time	Method
Measurement of pharmacokinetic (PK) parameter, Tmax, in MF, PV, PV-MF or ET-MF patients	Day 1, Day 2, and Day 15	Measurement will be using extensive PK sampling
Measurement of pharmacokinetic (PK) parameter, CL/F, in MF, PV, PV-MF or ET-MF patients	Day 1, Day 2, and Day 15	Measurement will be using extensive PK sampling
Measurement of pharmacokinetic (PK) parameter, T1/2, in MF, PV, PV-MF or ET-MF patients	Day 1, Day 2, and Day 15	Measurement will be using extensive PK sampling
Measurement of pharmacokinetic (PK) parameter, Vz/F, in MF, PV,PV-MF or ET-MF patients	Day 1, Day 2, and Day 15	Measurement will be using extensive PK sampling
Measurement of pharmacokinetic (PK) parameter, AUC, in MF, PV,PV-MF or ET-MF patients	Day 1, Day 2, and Day 15	Measurement will be using extensive PK sampling
Measurement of pharmacokinetic (PK) parameter, Cmax, in MF, PV,PV-MF or ET-MF patients	Day 1, Day 2, and Day 15	Measurement will be using extensive PK sampling
Measurement of pharmacokinetic (PK) parameter, MRT, in MF, PV,PV-MF or ET-MF patients	Day 1, Day 2, and Day 15	Measurement will be using extensive PK sampling

Trial Locations

Locations (1)

Revive Research Institute; 🇺🇸 Sterling Heights, Michigan, United States